Anupama Kalsekar

Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma

Jennifer Leigh Crombie, Monika P. Jun, Tongsheng Wang, Alex Mutebi et autres

This study used COTA de-identified data (2010-2021) of patients in the US to explore outcomes of novel therapies in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in real-world settings. Demographics, clinical characteristics, and clinical outcomes of patients with R/R DLBCL who received …

us (code pays fourni par la source)

P1169: COMPARISON OF REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH EPCORITAMAB VS CHEMOIMMUNOTHERAPY

Andrew Ip, Allison Claire Rosenthal, Alex Mutebi, Tongsheng Wang et autres

Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) experience substantial burden of disease and suboptimal clinical outcomes. There is currently no clear standard of care for patients with R/R LBCL who have …

us (code pays fourni par la source)

P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS

Allison Claire Rosenthal, Monika P. Jun, Javier L Munoz, Tongsheng Wang et autres

Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Newly approved treatments for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and large B-cell lymphoma (LBCL) include chimeric antigen receptor T-cell (CAR T) therapy, polatuzumab vedotin plus bendamustine and rituximab (pola-BR) and tafasitamab plus …

us, dk (code pays fourni par la source)

RACIAL AND ETHNIC REPRESENTATION IN LARGE B‐CELL LYMPHOMA TRIALS AND REAL‐WORLD DATABASES

Javier L Munoz, Alex M. Mutebi, Tingrong Wang, Guicheng Zhang et autres

Introduction: In large B-cell lymphoma (LBCL) trials, racial and ethnic representation is difficult to determine due to underreporting in some regions, or because some patients may not provide data. It is difficult to understand the full extent of any underrepresentation of specific …

us (code pays fourni par la source)

REAL‐WORLD OUTCOMES WITH NOVEL THERAPIES IN R/R DLBCL

Jennifer Leigh Crombie, M. Jun, T. Wang, Alex M. Mutebi et autres

Introduction: Outcomes have historically been poor for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Despite an increase in approved R/R DLBCL treatment options, clinical outcomes of these therapies remain less certain. Novel treatments for these patients include chimeric antigen receptor …

us (code pays fourni par la source)

COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB‐BASED REGIMENS, AND TAFASITAMAB‐BASED REGIMENS

Allison Claire Rosenthal, Mira Jun, Javier L Munoz, Trent Wang et autres

Introduction: Epcoritamab, an off-the-shelf subcutaneous CD3xCD20 T-cell–engaging, bispecific antibody that redirects CD3+ T cells to eliminate malignant CD20+ B cells, has shown deep and durable responses in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patient populations, including those with difficult-to-treat LBCL. In the …

us, dk (code pays fourni par la source)

Comparison of clinical outcomes in patients with relapsed/refractory large B‐cell lymphoma treated with epcoritamab versus chemoimmunotherapy

Andrew Ip, Allison Claire Rosenthal, Alex M. Mutebi, Trent Wang et autres

Introduction: There is currently no clear standard of care for patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) who have failed ≥2 prior lines of therapy (LOTs); although chemoimmunotherapy (CIT) regimens are the most commonly used therapies, outcomes are not …

us (code pays fourni par la source)

PCN43 SYSTEMATIC LITERATURE REVIEW OF THE EFFICACY OF SECOND-LINE OR LATER TREATMENTS FOR RECURRENT OR METASTATIC CERVICAL CANCER

Julie Glanville, Marie Louise Edwards, Anita Fitzgerald, Sonia J. Pulgar et autres

gb, us (code pays fourni par la source)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Phil C. McEwan, Samantha Webster, Thomas T. Ward, Michael Brenner et autres

BACKGROUND: As treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated with faster disease …

gb, us (code pays fourni par la source)

A clinician’s guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective

Phil C. McEwan, Nowlan Selvapatt, Ashley S Brown, Mark R. Thursz et autres

BACKGROUND AND AIMS: The hepatitis C virus (HCV) remains a considerable public health challenge. Novel direct-acting antiviral (DAA) regimens offer high cure rates and the promise of reduced HCV incidence and prevalence following the up-scaling of treatment. This has focused attention towards …

gb, Afrique du Sud, au, us (code pays fourni par la source)

Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies

Hayley Bennett, Jason P. Gordon, Beverley Jones, Thomas T. Ward et autres

gb, au, us (code pays fourni par la source)

Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease

Thomas T. Ward, Jason P. Gordon, Beverley Jones, Hayley Bennett et autres

gb, au, us (code pays fourni par la source)